/Companies

BioGene Therapeutics

Austin, US · Founded 2024 · Texas corporation

Find your way into BioGene Therapeutics

Sign up to see every warm intro you have to BioGene Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the BioGene Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Founders & leadership

SVSTEPHEN VAN DEVENTER
STEPHEN VAN DEVENTERExecutive

Board

DS
DEEPAK SAMPATHBoard director
PL
PATROSKI LAWSONBoard director
SG
STEVE GLOVERBoard director
RP
RAJ PRUTHIBoard director
DT
DAVID TYRONNE HOWTONBoard director

Reported raises · per SEC filings

Form D private placements

$11.1M disclosed across 5 rounds · 2025–2026

▶$3MraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • STEPHEN VAN DEVENTERExecutive Officer, Director
  • DEEPAK SAMPATHDirector
  • PATROSKI LAWSONDirector
  • STEVE GLOVERDirector
  • RAJ PRUTHIDirector
  • DAVID TYRONNE HOWTONDirector
Offering amount
$3M
Amount sold
$3M
First sale
Jun 2026
Incorporated
Corporation, Texas, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • STEPHEN VAN DEVENTERExecutive Officer, Director
  • DEEPAK SAMPATHDirector
  • PATROSKI LAWSONDirector
  • STEVE GLOVERDirector
  • RAJ PRUTHIDirector
  • DAVID TYRONNE HOWTONDirector
Offering amount
$250K
Amount sold
$250K
First sale
Aug 2025
Incorporated
Corporation, Texas, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • STEPHEN VAN DEVENTERExecutive Officer, Director
  • DEEPAK SAMPATHDirector
  • PATROSKI LAWSONDirector
  • STEVE GLOVERDirector
  • RAJ PRUTHIDirector
  • DAVID TYRONNE HOWTONDirector
Offering amount
$250K
Amount sold
$250K
First sale
Aug 2025
Incorporated
Corporation, Texas, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • STEPHEN VAN DEVENTERExecutive Officer, Director
  • DEEPAK SAMPATHDirector
  • PATROSKI LAWSONDirector
  • STEVE GLOVERDirector
  • RAJ PRUTHIDirector
  • DAVID TYRONNE HOWTONDirector
Offering amount
$3M
Amount sold
$3M
First sale
Mar 2026
Incorporated
Corporation, Texas, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedJul 2026 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • STEPHEN VAN DEVENTERExecutive Officer, Director
  • DEEPAK SAMPATHDirector
  • PATROSKI LAWSONDirector
  • STEVE GLOVERDirector
  • RAJ PRUTHIDirector
  • DAVID TYRONNE HOWTONDirector
Offering amount
$4.5M
Amount sold
$4.5M
First sale
Apr 2025
Incorporated
Corporation, Texas, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

How much funding has BioGene Therapeutics raised?
BioGene Therapeutics has disclosed $11.1M raised across 5 rounds.
Where is BioGene Therapeutics headquartered?
BioGene Therapeutics is headquartered in Austin, US.